The Old Stool Test and the New One: FOBT vs FIT

Two Different Chemistries, One Same Goal

Both FOBT and FIT check a stool sample for hidden blood that can signal a polyp or early colorectal cancer, but they detect that blood through different chemistry. The older, guaiac-based FOBT uses a chemical reaction that changes color in the presence of the compound found in blood, a method that has been in clinical use for decades. FIT instead uses an antibody that reacts specifically to human hemoglobin, the protein in red blood cells 1Ref 1Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.That FIT uses an antibody specific to human hemoglobin, with pooled sensitivity of about 79% and specificity of about 94% for colorectal cancer — used to describe FIT's mechanism and to give its accuracy figures, in contrast with the older guaiac FOBT..

That specificity is the practical difference that matters most: an antibody reacting only to human blood is less likely to be thrown off by something else in the sample, while a general chemical color-change reaction has more room for other substances to interfere. Guideline bodies and most current screening programs have shifted toward the fit test — meaning FIT specifically — as the stool test with the accuracy numbers behind it. Both tests aim at the same underlying signal; only one of them has been the subject of the large modern accuracy studies that current screening guidance actually cites.

What FIT's Accuracy Numbers Actually Show

A meta-analysis pooling FIT studies found the test correctly identified about 79% of colorectal cancers in a screening population and correctly cleared about 94% of people who did not have cancer 1Ref 1Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.That FIT uses an antibody specific to human hemoglobin, with pooled sensitivity of about 79% and specificity of about 94% for colorectal cancer — used to describe FIT's mechanism and to give its accuracy figures, in contrast with the older guaiac FOBT.. Those numbers are specifically FIT's; there is no equivalent modern meta-analysis comparing guaiac FOBT head-to-head under the same conditions, which is itself part of why current guidelines report and recommend FIT specifically rather than FOBT broadly.

That gap in the newer literature isn't a knock against FOBT's basic premise — checking for hidden blood works, which is why FIT still checks for the same thing — it just means the antibody-based version is the one with contemporary, quantified accuracy data behind it.

Where FIT Sits in Current Screening Guidelines

Professional guidelines rank annual FIT alongside colonoscopy every ten years as first-tier colorectal cancer screening options, with newer stool-DNA testing and CT colonography ranked as second-tier alternatives 2Ref 2Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing and CT colonography as second-tier — used to explain that current guidelines rank FIT specifically as first-tier, not FOBT by name.. That ranking reflects FIT specifically, not the older guaiac FOBT test by name, which is a strong signal about which stool test current practice has actually settled on.

Annual repetition is part of what makes FIT work as a strategy in the first place: a single missed cancer in one year's sample has another chance to be caught twelve months later, which is baked into how its accuracy numbers were studied and reported 2Ref 2Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing and CT colonography as second-tier — used to explain that current guidelines rank FIT specifically as first-tier, not FOBT by name..

Where Cologuard Fits Into This Comparison

FOBT and FIT aren't the only stool-based options. Cologuard adds a DNA analysis on top of the same blood-detection chemistry FIT uses, screening for genetic markers linked to colorectal cancer and polyps in addition to blood 3Ref 3Imperiale TF, Porter K, Zella J, et al. (BLUE-C Study Investigators) (2024).Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.Current-generation Cologuard performance, which combines DNA marker analysis with the same blood-detection chemistry FIT uses — used to place Cologuard as a third, related stool-based option distinct from both FOBT and FIT.. It's typically used less often than annual FIT, which shifts more of the screening burden onto that single sample being right.

The fit vs cologuard question is a separate comparison from FOBT vs FIT: Cologuard and FIT are both modern tests with contemporary accuracy data behind them, while FOBT is the older chemistry that current guideline language has largely moved past.

What a Positive Result Means, Whichever Test Flagged It

A positive result on either an older FOBT or a current FIT is not a cancer diagnosis by itself — it means blood was detected in the stool sample, and the next step is a colonoscopy to find the source 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test is covered as screening rather than diagnostic, and that Medicaid coverage for colorectal cancer screening varies by state — used to explain what happens, and what it costs, after either stool test comes back positive.. Medicare and most private insurers cover that follow-up colonoscopy as a screening exam rather than a diagnostic one, specifically because a positive stool test is what triggered it 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test is covered as screening rather than diagnostic, and that Medicaid coverage for colorectal cancer screening varies by state — used to explain what happens, and what it costs, after either stool test comes back positive..

That coverage rule doesn't distinguish between which stool test came back positive; what matters for billing purposes is that the colonoscopy was triggered by a positive screening result, not a symptom. Medicaid coverage for that same follow-up colonoscopy varies by state, even though the underlying screening recommendation is federal and the same everywhere 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test is covered as screening rather than diagnostic, and that Medicaid coverage for colorectal cancer screening varies by state — used to explain what happens, and what it costs, after either stool test comes back positive..

That state-by-state variation is worth checking directly rather than assumed, particularly for anyone whose coverage comes through Medicaid rather than Medicare or an employer plan. The screening test itself, whether FOBT, FIT, or Cologuard, does not change that state-level answer — only the fact that the colonoscopy followed a positive screening result does.

Why the Two Names Still Get Confused on Paperwork

FOBT and FIT sometimes appear interchangeably on older paperwork, insurance codes, or a lab requisition that hasn't caught up to which specific chemistry is actually being used, which is exactly why the two names get confused in the first place. Confirming which test a kit or a lab order actually performs matters, since FIT is the version with contemporary accuracy data and the one current guidelines rank as first-tier 2Ref 2Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing and CT colonography as second-tier — used to explain that current guidelines rank FIT specifically as first-tier, not FOBT by name..

Someone handed an at-home kit labeled simply as a 'stool blood test' is worth asking about directly, since the two versions differ in how reliable the result is — rather than assuming both kits work identically just because they arrive in a similar box.

The Practical Takeaway: Ask Which Test, Not Just 'A Stool Test'

The most useful move for anyone handed a screening order or an at-home kit is to ask specifically whether it's a FIT or an older FOBT, rather than treating 'stool blood test' as one interchangeable thing. FIT is the version with the accuracy numbers behind it and the one professional guidelines rank as a first-tier screening option 2Ref 2Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking of annual FIT and colonoscopy every ten years as first-tier options with stool-DNA testing and CT colonography as second-tier — used to explain that current guidelines rank FIT specifically as first-tier, not FOBT by name., which makes it the more defensible default when there's a choice.

Whichever test is actually used, a positive result leads to the same next step — a colonoscopy — and the same coverage rule applies once that colonoscopy is triggered by the positive screening result rather than a symptom 4Ref 4American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That a follow-up colonoscopy after a positive stool test is covered as screening rather than diagnostic, and that Medicaid coverage for colorectal cancer screening varies by state — used to explain what happens, and what it costs, after either stool test comes back positive.. Consistency, actually returning the kit every year regardless of which test it is, still matters more for long-term protection than which single test scores marginally better on paper.